Synpromics was proud to be featured at the launch of the inaugural joint report from the Alliance for Regenerative Medicine (ARM) and the UK BioI
Synpromics joined the BSGCT in Sheffield at the end of June to share the latest progress in gene and cell therapy.
On the first day, CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum.
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York.
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.